



**October
19-21, 2016**

Sheraton Montreal Airport Hotel
Montréal, Quebec



Join us



**October
12-14, 2017**

Toronto, Ontario
#CHC17



Who we are

Hypertension Canada is the country's only national non-profit organization dedicated solely to the prevention and control of hypertension and its complications. Powered by a professional volunteer network of the nation's leading multidisciplinary experts, Hypertension Canada pursues its mission through research, professional and public education, and advocacy for healthy environments. Learn more at www.hypertension.ca.

What drives us

At Hypertension Canada, our mission and vision are at the core of everything we do. We foster the health care professional's network for excellence in hypertension research, education and care.

Mission: Advancing health through the prevention and control of high blood pressure and its complications.

Vision: Canadians will have the healthiest and best managed blood pressure in the world.

How we'll get there

► Inspire innovation

Hypertension Canada is proud to invest in promising and talented hypertension investigators. We support the important work of current and future investigators through strategic partnerships; we foster career mentoring and succession planning; and collaboratively work with clinicians and patients to set hypertension research priorities.

► Invest in education

Hypertension Canada creates and publishes the world-renown clinical practice guidelines for hypertension diagnosis, treatment, and control, and supports health care professionals in their application. The Hypertension Canada Guidelines are developed by a multi-disciplinary task force and are rigorously reviewed and annually updated. We provide a suite of accredited educational programs for health care professionals based on the guidelines, and create educational resources for professionals to use with their patients.

► Initiate conversations

Hypertension Canada works with stakeholders, partners, and government to improve awareness, prevention, and treatment of hypertension and its complications. We make it our business to keep abreast of issues affecting people with hypertension and the professionals who treat them, and seek opportunities to make positive changes that bring us closer to achieving our mission.

► Intentionally engage

Our work is most effective when we collaborate. Hypertension Canada proudly leads the conversation on emerging hypertension issues, and engages our community in innovative new ways. We strive to connect with diverse professionals and partners to chart the most effective and collaborative approaches to our work. And together, we advance health through the prevention and control of hypertension and its complications.

Wednesday, October 19, 2016

18:00 - 18:10	<p>Opening Remarks Room: Petit Salon <i>Dr. Ross Feldman, Canadian Hypertension Congress Chair</i></p>
18:10 - 19:00	<p>Opening Panel Discussion</p> <p>Topic: Especially in Cases of Intensive Intervention, How Might National Pharmacare Affect Patient and Provider Access to Antihypertensive Medications in Canada?</p> <p><i>Moderator: Dr. Milan Gupta</i></p> <p><i>Panelists: Dr. Tavis Campbell, Mr. Glen Doucet, Ms. Sarah Beech, Mr. Denis Morrice</i></p> <p>Closing Remarks <i>Dr. Ernesto Schiffrin, President and Chair of the Board, Hypertension Canada</i></p>
19:00 - 20:30	<p>Poster Session # 1 Room: Grand Salon</p> <p>Biomedical Research Track</p> <p>BMR1 Resveratrol Attenuates Hyper Proliferation of Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats: Role of ROS and ROS-Mediated Signaling - <i>Sara Almajdoob</i></p> <p>BMR2 Angiotensin-II-induced Expression of the Early Growth Response Protein-1 is attenuated by c-AMP Agonists in Vascular Smooth Muscle Cells - <i>Estelle Rolande Simo Cheyou</i></p> <p>BMR3 The Effect of Bradykinin and Bradykinin B2 Receptors on High-Glucose-Induced Senescence of C-Kit Positive CPCs - <i>Yuning Sun</i></p> <p>BMR4 Canagliflozin, a Sodium-Glucose Co-Transporter 2 (SGLT-2) Blocker, Normalizes Blood Glucose without Affecting Systemic Blood Pressure and Intrarenal Renin-Angiotensin System Gene Expression and Kidney Injury in Akita Mice with Type 1 Diabetes - <i>Chin-Han Wu</i></p> <p>BMR5 Induction of Human Endothelin-1 Overexpression for 3 months Causes Blood Pressure Rise and Small Artery Endothelial Dysfunction and Stiffening - <i>Suellen Coelho</i></p> <p>BMR6 Statin Therapy Modulates the Adiponectin Receptor Pathway in Circulating Monocytes in Subjects with Severe Atherosclerosis and in Hypertensive Subjects High-risk for Cardiovascular Disease - <i>Karina Gasbarrino</i></p> <p>BMR7 Evaluation of the Cardiovascular and Kidney Functions of the Male Wistar Rats submitted to a Model of Arterial Hypertension after Treatment with the Aqueous Extract of Baccharis Trimera - <i>Rodrigo Liberato Goncalves Vianna</i></p> <p>BMR8 Alamandine and Angiotensin-(1-7) Prevent Programming of Cardiac Dysfunction Induced by Neonatal Exposure to High Oxygen in Rats - <i>Thuy-An Mai-Vo</i></p> <p>BMR9 Regional Heterogeneity in the Stoichiometry of Vascular Phosphate and Calcium Accrual: Differential Dependency on Vitamin K Status - <i>Jason Zelt</i></p> <p>BMR10 SREBP2 Expression is regulated by GPER Differentially in HepG2 Cells vs. Human Hepatocytes - <i>Qingming Ding</i></p> <p>BMR11 Matrix Metalloproteinase 2 Knockout Projects from Angiotensin II-Induced Vascular Injury - <i>Julio Cesar Fraulab Aquino</i></p> <p>Clinical Research Track</p> <p>CR1 The Arterial Health Impact of Intradialytic Pedaling Exercise in a Hemodialysis Population - <i>Alexandra Cooke</i></p> <p>CR2 Predicting Cognitive Decline in Older Adults: Aortic Stiffness and Framingham Cardiovascular Risk Scores - <i>Xavier Trudel</i></p> <p>CR3 Dietary Sodium and Potassium Intake in a Referred Population with Difficult to Control Hypertension - <i>Swapnil Hiremath</i></p> <p>CR4 The Relationship between Hypertensive Disorders of Pregnancy and Incident Hypertension: A Couple Analysis - <i>Anne-Sophie Brazeau</i></p> <p>CR6 Angiotensin-Like-2 is Positively Correlated with Aortic Stiffness and Mortality after Kidney Transplantation - <i>Marie-Pier Desjardins</i></p> <p>CR7 Self Measurement of Blood Pressure Using an Office Automated Device - <i>Monica Ilinca</i></p> <p>CR8 Effects of Fixed Versus Auto-Titrating Continuous Positive Airway Pressure on Vascular Function in Patients with Resistant Hypertension and Obstructive Sleep Apnea - <i>Karen Tran</i></p> <p>CR9 Environmental Factors and Hypertension: The Role of Particulate Matter (PM) - <i>Omar Albassam</i></p> <p>CR10 Aortic Reservoir Function and Aortic-to-Brachial Stiffness Gradient in a Dialysis Population - <i>Catherine Fortier</i></p> <p>CR11 Exercise and Antioxidant Intake in Aging Normotensive and Hypertensive Individuals - <i>Stéphanie Mercier</i></p> <p>CR12 Optimal Blood Pressure Readings Aim to Renal Protection in Chronic Kidney Diseases in the Geriatric Population - <i>Samia LL Rizk</i></p>
19:00 - 20:30	<p>President's Reception Room: Grand Salon</p>

Thursday, October 20, 2016

Friday, October 21, 2016

	Biomedical Research Track Room: Petit Salon	Clinical/Outcomes/Population Research Track Room: Grand Salon
	Each 15 min session includes a 5 min Q&A Each 30 min session includes a 10 min Q&A	Each 15 min session includes a 5 min Q&A Each 30 min session includes a 10 min Q&A
07:45 - 8:45	Hypertension Canada's Annual General Meeting with Continental Breakfast Room: Soulange-Mercier-Laurentien-Dorval	
09:00 - 10:30	Biomedical # 1 <i>Co-chairs: Drs. Dylan Burger & Pierre Paradis</i> 09:00 y/δ T Cells Play a Role in Development of Hypertension (2016 Hypertension Canada-Canadian Vascular Network Scholar award winning Abstract) – Antoine Caillon 09:15 Neonatal O2 Exposure Programs the Renin-Angiotensin System in Adipose Tissue of Adult Male Rats – Marie-Amélie Lukaszewski 09:30 The Role of Endoplasmic Reticulum Stress in the Development of Essential Hypertension – Safaa Najel 09:45 Calcitriol Treatment Modifies Left Ventricular Hypertrophy in an Experimental Model of Chronic Kidney Disease – Mandy Turner 10:00-10:30 STATE OF THE ART — Microparticles in Hypertension and Cardiovascular Disease: Does What's Inside Count? – Dr. Dylan Burger	Clinical # 1 <i>Co-chairs: Drs. Donna McLean & George Dresser</i> 09:00 - 09:30 STATE OF THE ART — Examining the Potential of Nurse Practitioners in Hypertension Care – Dr. Donna McLean 09:30 Arterial Stiffness for the Early Prediction of Pre-eclampsia Compared with Clinical Characteristics, Uterine Artery Doppler Indices, and Angiogenic Biomarkers – Kim Phan 09:45 Use of Hypertension Canada/Canadian Hypertension Education Program (CHEP) Guidelines in Teaching in Canadian Pharmacy Schools – Delaney Montague 10:00 Web-Based Dietary Sodium Screening Tools Improve Sodium Knowledge, Attitudes and Behaviours – Katherine Jefferson 10:15 Coffee – Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study With Felodipine – George Dresser
10:30 - 11:00	Break in Mezzanine	
11:00 - 12:30	Biomedical # 2 <i>Co-chairs: Drs. Noriko Daneshitalab & Julie Lavoie</i> 11:00 miR-431 as a Potential Master Regulator in Angiotensin II-induced Vascular Injury – Ku-Geng Huo 11:15 Effect of High Glucose Exposure on Endothelial Micro Particle Formation and Composition – Maddison Turner 11:30 The Angiotensin IV Receptor: A Potential Target for Cerebrovascular and Cognitive Rescue in a Mouse Model of Alzheimer's Disease (2016 Hypertension Canada-Canadian Vascular Network Scholar award winning Abstract) – Jessica Royea 11:45 Attenuating Dietary Phosphate Impacts Vascular Calcification and Associated Vascular Stiffening in Experimental Chronic Kidney Disease – Bruno Svajger 12:00-12:30 STATE OF THE ART — The Immune System & Cardiovascular Disease – Dr. Ernesto Schiffrin	Clinical # 2 <i>Co-chairs: Drs. Martin Myers & Doreen Rabi</i> 11:00 - 11:30 STATE OF THE ART — The Systolic Blood Pressure Intervention Trial (SPRINT) and the Implications on Treatment – Dr. William Cushman 11:30 Statin Therapy in Rheumatoid Arthritis May Improve Arterial Stiffness in Women but Not in Men: A Preliminary Analysis – Yessica-Haydee Gomez 11:45 Blood Pressure Reduction by Prescribing Pharmacists – Insights from the Multicentre Randomized Rx EACH Study – Ross Tsuyuki 12:00 A Systematic Review of Population Based Interventions to Reduce Blood Pressure – Claudio Del Grande
12:30 - 14:00	Lunch in the Soulange-Mercier-Laurentien-Dorval	
14:00 - 15:30	14:00 Senior Investigator Award Lecture — Molecular Studies of Vascular Smooth Muscle: Looking Back and Jumping Forward – Dr. Mansoor Husain 14:30 Vancouver 2010 Lecture Home — Home BP Monitoring: Primary Role in Hypertension Management – Dr. George Stergiou 15:00 Hypertension Canada's Recognition Awards – Dr. Nadia Khan	
15:30 - 17:30	Break in Petit Salon	
15:30 - 17:30	Poster Session # 2A Room: Petit Salon Biomedical Research Track BMR1 Transient Neonatal High Oxygen Exposure Accelerates Adult Cardiac Baseline and ANG II-Induced Prooxidative and Proinflammatory Responses - Muhammad Mian BMR2 Evaluation of Different Metrics for the Assessment of Arterial Stiffness - Camille Leblanc BMR3 Natriuretic Peptide Receptor-C Agonist Attenuates the Enhanced Expression of Gqα/PLCβ1 Proteins and Vascular Smooth Muscle Cell Hypertrophy in Spontaneously Hypertensive Rats: Role of ROS and ROS-Mediated Signaling - Ashish Jain BMR4 Resveratrol Attenuates Angiotensin II-induced Vascular Smooth Muscle Cell Hypertrophy: Molecular Mechanisms - Ekhtear Hassain BMR5 Chronic Inflammation and Sympathetic Nerve Mediated Contractions in Rat Isolated Caudal Artery - Jocelyn Foto Soh BMR6 Early Growth Response Protein-1 Expression by Hydrogen Peroxide is mediated via Protein Kinase C-Dependent Activation of MAPK and Protein Kinase B Signaling in Vascular Smooth Muscle Cellse - Vincent Rondeau BMR7 PBI-4050 Exerts Renoprotection in a Mouse Model of Renin-Dependent and Streptozotocin-Induced Kidney Injury - Jean-Francois Thibodeau BMR8 Concentration-Dependent Effects of Metformin on the Vascular Endothelium - Chris Triggie BMR9 Renin Overload - Jeffrey Alfonsi BMR10 Mapping of Chromosome 2 Regions Linked to Vascular Inflammation Using Congenic Rats - Sofiane Ouerd BMR11 Salt Sensitive Hypertension in Chronic Kidney Disease - Samera Nademi BMR12 Effect of Phase II Enzyme Inducer, Sulforaphane on Hypertension and Renal Arterial Structure - Ali Banigesh Clinical/Outcomes/Population Research Track CR1 A Trend Analysis of Hypertension Disease Deaths in Sri Lanka during 2000-2006 - Pinithi Siriwardana CR2 Attitudes of Obstetrical Medicine Specialists about Out-of-Office Blood Pressure Measurement in Canada for the Diagnosis of White Coat Hypertension - Karen Tran CR3 Masked Hypertension and Effort-Reward Imbalance among 2369 White-Collar Workers - Philippe Boucher CR4 Improvement in Blood Pressure Following Group-Based Diabetes Prevention Programs in Families with Recent Gestational Diabetes - Anne-Sophie Brazeau CR5 Dietary Calcium Intake: Does it affect Vascular Health? - Shubhabrata Das CR6 Regional Vascular Stiffness in Response to Nitroglycerin and Their Impact on Arterial Stiffness Gradient - Catherine Fortier CR7 The Effect of Alcohol Consumption Reduction on Blood Pressure: A Systematic Review and Meta-Analyses of Intervention Studies - Michael Roerecke CR8 The Relationship of Vitamin D and Parathormone Levels with Hypertension: Is it Different in White Coat or Sustained Hypertension? - Ferit Akgül CR9 The Alberta Vascular Risk Reduction Community Pharmacy Project in Patients with CKD (Rx EACH-CKD) - Yazid Al Hamarneh CR10 Non-Invasive and Continuous Blood Pressure Prediction from Pulse Transit Time Using ECG and PPG Signals - Shrimanti Ghosh CR11 Screening for Hypertension during Consultation in a Walk-in Service: Study Protocol for a Pilot Study - André Michaud CR13 Coronary Blood Flow is reduced in Patients with Hypertension which should increase the Risk of Myocardial Ischemia with Development of Coronary Artery Disease - Simon Rabkin	

	Biomedical Research Track Room: Petit Salon	Clinical/Outcomes/Population Research Track Room: Salon La Tour	Primary Care Track Room: Grand Salon
	Each 15 min session includes a 5 min Q&A Each 30 min session includes a 10 min Q&A	Each 15 min session includes a 5 min Q&A Each 30 min session includes a 10 min Q&A	Each 20 min session includes a 5 min Q&A Each 30 min session includes a 10 min Q&A
06:30 - 7:45	Breakfast Symposium in the Soulange-Mercier-Laurentien-Dorval Topic: Intensive BP Intervention <i>Moderator: Dr. Ross Feldman</i> <i>Panelists: Dr. George Dresser, Dr. Phil McFarlane & Dr. Sheldon Tobe</i>		
08:00 - 09:30	Biomedical # 3 <i>Chair: Dr. Robert Gros</i> 08:00 - 08:30 STATE OF THE ART — The Role of Glucagon Like Peptides in Cardiovascular Disease – Dr. Mansoor Husain 08:30 Hypertensive Mice Exhibit Elevated Urinary Microparticles despite Normal Renal Histology – Jamie Ghossein 08:45 Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Deficiency Attenuates Systemic Hypertension via Down-Regulation of Intrarenal Renin-Angiotensin System Gene Expression in Type 1 Diabetic Akita Nrf2 knockout (KO) Mice – Shuling Zhao 09:00 Endothelin-1 Exaggerates Type-1 Diabetes-Accelerated Atherosclerosis through NADPH Oxidases 1 and 4 – Sofiane Ouerd 09:15 Warfarin Treatment Modifies the Pattern of Mineral Accrual in an In Vitro Model of Vascular Calcification – Paul Jeronimo	Clinical # 3 <i>Co-chairs: Drs. Simon Rabkin & Ross Tsuyuki</i> 08:00 Fragmented Sleep, Obstructive Sleep Apnea, and Sympathetic Firing Incidence during Wakefulness – John Floras 08:15 Combined Effect of Job Strain and Psychological Distress on the Risk of Recurrent Myocardial Infarction – Xavier Trudel for Diane Tuyishimire 08:30 Vascular Function and Structure Changes Along with High Blood Pressure in Young Adults Born Very Preterm – Julie De Meulemeester 08:45 Effort-Reward Imbalance at Work and the Prevalence of Uncontrolled Hypertension among Treated Workers – Xavier Trudel 09:00 - 09:30 STATE OF THE ART — Hypertension and Aortic Aneurysms: Towards an Understanding of the Clinical and Biological Linkage – Dr. Simon Rabkin	Primary Care # 1 Core Curriculum in Hypertension <i>Co-chairs: Drs. Ross Feldman & Doreen Rabi</i> 08:00 Intensive Blood Pressure Lowering: Important Considerations in Post-SPRINT World – Dr. Doreen Rabi 08:20 Which Blood Pressure, Which Method & Why? – Dr. Kaberi Dasgupta 08:40 Which Drug? Which Drug Combination? – Dr. George Dresser 09:00 Complicated and Resistant Hypertension: What to do When the Going Gets Tough – Dr. Sheldon Tobe
09:30 - 10:00	Break in Mezzanine		
10:00 - 11:30	Biomedical # 4 <i>Co-chairs: Drs. John Chan & Jeffrey Dickhout</i> 10:00 Role of K-Cl Cotransporter Type 3 in Mice Cardiometabolic Physiology – Alexandre Garneau 10:15 Adiponectin Promotes Macrophage-mediated Cholesterol Efflux with High Efficiency and Modulates HDL Biogenesis – Karina Gasbarino 10:30 The Involvement of the IRE1 Pathway in Vascular Fibrosis and Stiffening – Victor Tat 10:45 Increases in von Willebrand Factor Levels Positively Correlate with Fibroblast Growth Factor-23 Levels, Left Ventricular Hypertrophy and Vascular Calcification in Experimental Chronic Kidney Disease with Calcitriol Supplementation – Cynthia Pross 11:00 - 11:30 STATE OF THE ART — Oxidative Stress in Diabetic Kidney Disease & Hypertension – Dr. John Chan	Clinical # 4 <i>Co-chairs: Drs. Robert Nolan & Stella Daskalopoulou</i> 10:00 - 10:30 STATE OF THE ART — PCSK9 Inhibitors in the Hypertensive Patient with Dyslipidemia – Dr. Jacques Genest 10:30 Feasibility Assessment of a Validated Blood Pressure Device for Chronic Disease Management via Cloud and Telemonitoring Technology – Sarah Melville 10:45 Reversibility of Arterial Stiffness after Kidney Transplantation: A Systematic Review and Meta-analysis – Aboubacar Sidibé 11:00 Carotid Femoral Pulse Wave Velocity is Responsive to Step Counts in Adults Treated for Hypertension and Diabetes – Kaberi Dasgupta 11:15 e-Counseling Adds Long-term Therapeutic Benefit to Usual Care for Hypertension in the REACH Trial – Robert Nolan	Primary Care # 2 Special Populations <i>Co-chairs: Drs. Donna McLean & Raj Padwal</i> 10:00 Hypertension in Children: A Practical Approach – Dr. Kevin Harris 10:30 Reducing the Risk of Heart Disease in Women: Under Treatment or Overkill? – Dr. Ross Feldman 11:00 Applying Hypertension Guidelines in the Frail Elderly – Dr. Raj Padwal
11:30 - 13:00	Lunch Symposium in the Soulange-Mercier-Laurentien-Dorval Topic: So You Think You're a Hypertension Expert? <i>Host: Dr. Phil McFarlane</i> <i>Panelists: Dr. George Dresser, Dr. Stella Daskalopoulou, Dr. Ernesto Schiffrin, Dr. Sheldon Tobe & Dr. Luc Trudeau</i>		
13:00 - 14:30	Vascular Network Symposium <i>Chair: Dr. Mansoor Husain</i> 13:00 Welcome & Introduction – Dr. Mansoor Husain 13:05 Collagen Signalling in Vascular Stiffening and Calcification – Dr. Michelle Bendeck 13:35 Large Animal Models of Cardiopulmonary Disease – Dr. Kurt Williams 14:00 Cardiometabolic Adaptations to Systemic Energy State – Dr. Bradford Hill	Primary Care Session # 3 Beyond Hypertension: Global Risk Reduction <i>Co-chairs: Drs. Denis Drouin & Lyne Cloutier</i> 13:00 Vascular Protection: 1) Lifestyle and Cardiovascular Diseases: An Update – Dr. Denis Drouin 13:30 Vascular Protection: 2) How to Structure an Exercise Prescription – Dr. Simon Bacon 14:00 Vascular Protection: 3) Reducing CV Risk in Hypertension: Beyond Blood Pressure – Dr. Milan Gupta	
14:30 - 15:00	Break in Mezzanine		
15:00 - 16:30	15:00 The Top 10 Research Priorities in Hypertension Management from Patients, Caregivers and Clinicians <i>Moderator: Dr. Ross Tsuyuki</i> <i>Panelists: Dr. Nadia Khan, Dr. Simon Bacon, Dr. Robert Gros</i> 16:00 Trainee Presentation Awards – Dr. Robert Gros	Primary Care Session # 4 Managing the Other Risk Factors and Hypertension Complications <i>Co-chairs: Drs. Ally Prebtani and Milan Gupta</i> 15:00 Diabetes Management: Beyond Metformin – Dr. Ally Prebtani 15:30 A Fib: What's the Score? What's the Drug for ...Rate? Rhythm? Thrombosis Prevention? – Dr. Paul Dorian 16:00 Dyslipidemia Guidelines: The End of Targets? Beyond Statins? – Dr. Paul Poirier	

Accreditation

The Continuing Professional Development (CPD) Office of the Faculty of Medicine of the University of Montreal is fully accredited by the Association of Faculties of Medicine of Canada (AFMC) and from the Quebec College of Physicians.

This activity, approved by the Continuing Professional Development (CPD) Office of the Faculty of medicine of the University of Montreal, is an Accredited Group Learning Activity under Section 1, as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada for a maximum of 12.25 hours.

This program meets the accreditation criteria of the College of Family Physicians of Canada and has been accredited by the University of Montreal for up to 12.25 Mainpro+ credits.

For all other participating professionals, this program provides a certificate of participation of 12.25 hours.

Participants must claim the number of hours according to their participation. In order to receive a certificate of completion or credits, complete the sign-up sheet at the registration desk before leaving.